Newly Described Human Antibody Prevents Malaria in Mice

March 21, 2018 Scipreneur Private Limited 0

Newly Described Human Antibody Prevents Malaria in Mice By: NIAID News Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, [..]

Molecular Cuisine for Gut Bacteria

March 19, 2018 Scipreneur Private Limited 0

Molecular Cuisine for Gut Bacteria By: EMBL News Scientific recipes to successfully grow and study gut bacteria in the lab: that’s what EMBL* scientists are publishing in Nature Microbiology on March 19. They report on the nutritional preferences and growth characteristics of 96 diverse gut bacterial strains. Their results will help scientists [..]

New Form of Electronic Matter

March 19, 2018 Scipreneur Private Limited 0

New Form of Electronic Matter By: Lois Yoksoulian | UIUC news Researchers have produced a “human scale” demonstration of a new phase of matter called quadrupole topological insulators that was recently predicted using theoretical physics. These are the first experimental findings to validate this theory. The researchers report their findings in [..]

Best Tricks For Self Motivation

March 16, 2018 Scipreneur Private Limited 0

    Best Tricks For Self Motivation By: Vijay Soni, Ph.D. | Founder and C.E.O. Scipreneur Where there’s no will, there’s no way. One of the best ways to improve your personal effectiveness is to master your motivation and find your drive. If you can master motivation, you can deal with life’s setbacks, [..]

Personalizing Wearable Devices

Personalizing Wearable Devices By Leah Burrows | Harvard John A. Paulson School of Engineering and Applied Sciences When it comes to soft, assistive devices — like the exosuit being designed by the Harvard Biodesign Lab — the wearer and the robot need to be in sync. But every human moves a [..]

ARCHANGEL SUMMIT 2018

ARCHANGEL SUMMIT 2018 Archangel [ARK-Angel] Summit is the annual gathering of mission-driven entrepreneurs, leaders, and professionals who want to do well by doing good. Saturday, September 8, 2018 – Metro Toronto Convention Centre South – Toronto, Canada                 Ticket pricing 2017 Summit highlights Archangel Summit [..]

New Tailored Tissue Adhesives by MIT Scientist

February 28, 2018 Scipreneur Private Limited 0

New Tailored Tissue Adhesives by MIT Scientist By: Anne Trafton | MIT News Office  After undergoing surgery to remove diseased sections of the colon, up to 30 percent of patients experience leakage from their sutures, which can cause life-threatening complications. Many efforts are under way to create new tissue glues [..]

U.S. FDA Approved ERLEADA™ for Prostate Cancer

February 28, 2018 Scipreneur Private Limited 0

U.S. FDA Approved ERLEADA™ for Prostate Cancer By: Janssen News The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved ERLEADA™ (apalutamide), a next-generation androgen receptor inhibitor,[1] for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). ERLEADA™ is the first FDA-approved [..]

Sandoz Announces US FDA Approval and Launch of Glatopa® for Relapsing Forms of Multiple Sclerosis

February 13, 2018 Scipreneur Private Limited 0

Sandoz Announces US FDA Approval and Launch of Glatopa® for Relapsing Forms of Multiple Sclerosis By: Novartis News Sandoz, a Novartis division, today announced the US FDA approval and launch of Glatopa® (glatiramer acetate injection) 40 mg/mL. Glatopa (glatiramer acetate injection) 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone®* (glatiramer [..]

Novartis Receives FDA Approval for Cosentyx® Label Update to Include Moderate-to-Severe Scalp Psoriasis

February 12, 2018 Scipreneur Private Limited 0

Novartis Receives FDA Approval for Cosentyx® Label Update to Include Moderate-to-Severe Scalp Psoriasis By: Novartis News Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis[1]. The updated label includes Cosentyx data in moderate-to-severe [..]

Flexible Lithium Battery for Wearable Electronics by Columbia Engineers

January 31, 2018 Scipreneur Private Limited 0

Flexible Lithium Battery for Wearable Electronics by Columbia Engineers By: Columbia University School of Engineering and Applied Science The rapid development of flexible and wearable electronics is giving rise to an exciting range of applications, from smart watches and flexible displays—such as smart phones, tablets, and TV—to smart fabrics, smart glass, transdermal [..]

FDA Approved Lutathera® of Novartis for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

January 26, 2018 Scipreneur Private Limited 0

FDA Approved Lutathera® of Novartis for Treatment of Gastroenteropancreatic Neuroendocrine Tumors By: Novartis Media Release Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) [..]

Daily Routine of Successful People

January 25, 2018 Scipreneur Private Limited 0

Daily Routine of Successful People By: Vijay Soni, Ph.D. | Founder and C.E.O. Scipreneur “The secret of your future is hidden in your daily routine.” — Mike Murdock The daily routine of a successful person has the same habits day in and day out. It won’t be easy to make the changes, all you [..]

Let’s Start a Startup!

January 25, 2018 Scipreneur Private Limited 0

Let’s Start a Startup! By: Vijay Soni, Ph.D. | Founder and C.E.O. Scipreneur “A startup is a temporary organization used to search for a repeatable and scalable business model” –  Steve Blank Setting up a startup is not easy. But if you have an idea that you think deserves to be shared, if you think that you [..]

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

January 25, 2018 Scipreneur Private Limited 0

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss By: Novartis Media Release Novartis today announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US. Voretigene neparvovec, [..]

Supercharged Antibiotics Could Turn Tide Against Superbugs

January 7, 2018 Scipreneur Private Limited 0

Supercharged Antibiotics Could Turn Tide Against Superbugs By: University of Queensland News An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world’s most dangerous superbugs. The supercharge technique , led by Dr Mark Blaskovich and Professor Matt Cooper from UQ’s Institute for [..]

First Step Toward Cell-Sized Robots

January 7, 2018 Scipreneur Private Limited 0

First Step Toward Cell-Sized Robots By: Tom Fleischman,  Cornell Chronicle  An electricity-conducting, environment-sensing, shape-changing machine the size of a human cell? Is that even possible? Cornell physicists Paul McEuen and Itai Cohen not only say yes, but they’ve actually built the “muscle” for one. With postdoctoral researcher Marc Miskinat the helm, the team has made [..]

FDA Granted Breakthrough Therapy Designation to Novartis Kisqali®

January 7, 2018 Scipreneur Private Limited 0

FDA Granted Breakthrough Therapy Designation to Novartis Kisqali® By: Novartis News Novartis announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with [..]

Promacta® of Novartis Receives FDA Breakthrough Therapy Designation for First-Line Use in Severe Aplastic Anemia (SAA)

January 7, 2018 Scipreneur Private Limited 0

Promacta® of Novartis Receives FDA Breakthrough Therapy Designation for First-Line Use in Severe Aplastic Anemia (SAA) Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Promacta®(eltrombopag) for use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic [..]

World Business Forum; Sydney

January 4, 2018 Scipreneur Private Limited 0

World Business Forum Sydney, May 30-31, 2018; Price TBA Come hear an amazing group of inspirational speakers who are paving their own way and challenging traditions in business. You’ll be inspired by fresh ideas, start rethinking the status quo, and leave ready to tackle your own business challenges in creative and [..]